BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1504408)

  • 1. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia.
    Kane BJ; Kuhn JG; Roush MK
    Ann Pharmacother; 1992; 26(7-8):939-47. PubMed ID: 1504408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.
    Grever M; Kopecky K; Foucar MK; Head D; Bennett JM; Hutchison RE; Corbett WE; Cassileth PA; Habermann T; Golomb H
    J Clin Oncol; 1995 Apr; 13(4):974-82. PubMed ID: 7707126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
    Kraut EH
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.
    Martin A; Nerenstone S; Urba WJ; Longo DL; Lawrence JB; Clark JW; Hawkins MJ; Creekmore SP; Smith JW; Steis RG
    J Clin Oncol; 1990 Apr; 8(4):721-30. PubMed ID: 2313337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term outcome of patients with hairy cell leukemia treated with pentostatin.
    Ribeiro P; Bouaffia F; Peaud PY; Blanc M; Salles B; Salles G; Coiffier B
    Cancer; 1999 Jan; 85(1):65-71. PubMed ID: 9921975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.
    Golomb HM; Dodge R; Mick R; Budman D; Hutchison R; Horning SJ; Schiffer CA
    Leukemia; 1994 Dec; 8(12):2037-40. PubMed ID: 7807991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Ho AD; Thaler J; Mandelli F; Lauria F; Zittoun R; Willemze R; McVie G; Marmont AM; Prümmer O; Stryckmans P
    J Clin Oncol; 1989 Oct; 7(10):1533-8. PubMed ID: 2789273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia.
    Dillman RO
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):27-36. PubMed ID: 14748654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
    Dearden CE; Else M; Catovsky D
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
    Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
    Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentostatin and purine analogs for indolent lymphoid malignancies.
    Ho AD; Hensel M
    Future Oncol; 2006 Apr; 2(2):169-83. PubMed ID: 16563086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cells.
    Triozzi PL; Avery KA; Grever MR; Kraut EH
    J Interferon Res; 1990 Oct; 10(5):535-40. PubMed ID: 2273300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.
    Grever MR
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():25-8. PubMed ID: 21599604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
    Guest JF; Smith H; Sladkevicius E; Jackson G
    Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
    Spiers AS
    Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentostatin in the treatment of hairy-cell leukemia.
    Grever MR; Doan CA; Kraut EH
    Best Pract Res Clin Haematol; 2003 Mar; 16(1):91-9. PubMed ID: 12670468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentostatin induces durable remissions in hairy cell leukemia.
    Cassileth PA; Cheuvart B; Spiers AS; Harrington DP; Cummings FJ; Neiman RS; Bennett JM; O'Connell MJ
    J Clin Oncol; 1991 Feb; 9(2):243-6. PubMed ID: 1988572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.
    Brogden RN; Sorkin EM
    Drugs; 1993 Oct; 46(4):652-77. PubMed ID: 7506651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.